Inclusion Criteria:

1. Histologically confirmed non-Hodgkin's lymphoma;

2. Patients whose clinical findings satisfy either of HLH 2004 standard or ASH2009
standard:

HLH2004 standard at least 5 criteria out of the following: Fever ≥ 38.5 ℃ for ≥ 7
days; hepatosplenomegaly; Cytopenias affecting ≥ 2 of 3 lineages in PB Hb < 9 g/L
Platelet < 100 x 109 /L ANC < 1.0 x 109 /L; Hypertriglyceridemia and/or
hypofibrinogenemia (fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L);
Hemophagocytosis in BM or spleen or LN; Low or absent NK-cell activity ( according to
local laboratory reference); Serum-ferritin ≥ 500 mcg/L ; Soluble CD25(sIL-2
receptor) ≥ 2,400 U/ml ;

3. New-diagnosed and untreated;

4. Understand and voluntarily sign an informed consent form, able to adhere to the study
visit schedule and other protocol requirements.

ASH2009 Standard

1. .At least 3 of 4:

1. Fever

2. Splenomegaly

3. Cytopenias (minimum 2 cell lines reduced)

4. Hepatitis

2. . And at least 1 of 4:

1. Hemophagocytosis

2. ↑ Ferritin

3. ↑ sIL2Rα (age based)

4. Absent or very decreased NK function 4. Other results supportive of HLH
diagnosis:

1. Hypertriglyceridemia

2. Hypofibrinogenemia

3. Hyponatremia

Exclusion Criteria:

1. Primary HLH.

2. HLH from rheumatic disorder (such as SLE, AOSD, antiphospholipid antibody syndrome)

3. Pregnancy (as determined by serum or urine test) or active breast feeding

4. Concomitant malignancy other than non-Hodgkin's lymphoma and need to treat;

5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary
myelofibrosis) which investigator it unsuitable to be enrolled into this clinical
trial;

6. Any potential drug abuse, medical, psychological or social conditions which may
disturb this investigation and assessment.

7. In any conditions which investigator considered ineligible for this study.